The company is now down since yesterday’s close of 11.16. It is currently trading at $10.90 quite a bit below the 50 day moving average which is $12.44 and well below the 200 day moving average of $14.74. The 50 day moving average went down $-1.54 or -12.39% and the 200 day average went down $-3.84 or -26.06%.
Investors are feeling more bullish on shares of Lexicon Pharmaceuticals, Inc. recently as indicated by the downtick in short interest. The firm realized a fall in short interest between September 15, 2017 and September 29, 2017 of -8.73%. Short interest decreased 1,409,211 over that period. The days to cover increased to 24.0 and the percentage of shorted shares is 0.14% as of September 29.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been the object of insider buying activity recently. Sam L. Barker, Director bought $12,500 worth of shares at an average price of $12.50 on Fri the 15th. That brings the Director’s holdings to $320,288 per an SEC filing yesterday. Lonnel Coats, President and CEO acquired $376,500 worth of shares at an average price of $12.55 on Fri the 15th. Coats now owns $413,962 of stock as reported to the SEC.
Lexicon Pharmaceuticals, Inc., launched on July 7, 1995, is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. The Business’s drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development..
A few notable investment firms have updated their holdings. As of the end of the quarter Candriam Luxembourg S.C.A. had bought 33,000 shares growing its stake by 12.7%. The value of the company’s investment in Lexicon Pharmaceuticals, Inc. increased from $3,729,000 to $4,820,000 a change of $1,091,000 since the last quarter. As of quarter end Ubs Group Ag had acquired a total of 1,848 shares growing its holdings by 73.1%. The value in dollars went from $36,000 to $72,000 a change of 100.0% quarter to quarter.
As of the end of the quarter Pacad Investment Ltd. had acquired a total of 1,898 shares growing its position 13.4%. The value of the investment in (LXRX) went from $196,000 to $265,000 increasing 35.2% for the reporting period. Cutler Group LP grew its ownership by buying 61,572 shares an increase of 9,650.8% as of 09/30/2017. Cutler Group LP claims 62,210 shares worth $764,000. The value of the position overall is up by 7,540.0%.
As of the last earnings report the EPS was $-1.33 and is expected to be $-1.47 for the current year with 105,581,000 shares currently outstanding. Next quarter’s EPS is forecasted at $-0.44 with next year’s EPS projected to be $-0.96.